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Vaccination is one of the most effective and cost-benefit interventions that prevent the mortality and reduce morbidity from infectious pathogens. However, the licensed influenza vaccine
induces strain-specific immunity and must be updated annually based on predicted strains
that will circulate in the upcoming season. Influenza virus still causes significant health problems worldwide due to the low vaccine efficacy from unexpected outbreaks of next epidemic
strains or the emergence of pandemic viruses. Current influenza vaccines are based on immunity to the hemagglutinin antigen that is highly variable among different influenza viruses
circulating in humans and animals. Several scientific advances have been endeavored to
develop universal vaccines that will induce broad protection. Universal vaccines have been
focused on regions of viral proteins that are highly conserved across different virus subtypes.
The strategies of universal vaccines include the matrix 2 protein, the hemagglutinin HA2 stalk
domain, and T cell-based multivalent antigens. Supplemented and/or adjuvanted vaccination in combination with universal target antigenic vaccines would have much promise. This
review summarizes encouraging scientific advances in the field with a focus on novel vaccine
designs.
Keywords: Universal vaccines, M2 protein, Stalk domain, T cell immunity, Supplemented vaccination
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Vaccination is a deliberate attempt to protect humans against disease. The modern
history of vaccination began in 1796, when Edward Jenner used a cowpox virus preparation from a milkmaid for prevention of smallpox. Since the time of Edward Jenner,
vaccination has controlled the 12 major diseases, at least in some parts of the world:
smallpox, diphtheria, tetanus, yellow fever, pertussis, Haemophilus influenzae type b
disease, poliomyelitis, measles, mumps, rubella, typhoid and rabies. The global campaign for smallpox vaccination was very successful so that this disease has disappeared
from natural occurring of smallpox in the world. Cases of poliomyelitis have been reduced by 99% thanks to vaccination in most parts of the world. Vaccinations against
many other diseases including influenza have made major headway. However, much
remains to be done.
Isolation of the first human influenza A virus in 1933 contributed to the identification of the cause of previous epidemics and pandemics of respiratory disease, as well
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as the development of influenza vaccines [1,2]. Influenza virus infections can occur in wild animals and livestock as well
as in all age groups of human populations. The resulting illness substantially contributes to work and school time losses,
increases in influenza-related hospitalizations, and deaths
[3-5].
Influenza virus contains eight segmented negative sense
RNA genomes within the lipid-bilayer envelope, which belongs to the family Orthomyxoviridae. There are three distinct
types of influenza virus, designated A, B, and C, with types A
and B of influenza viruses being the major pathogens in humans. Influenza A viruses occur in birds, humans, horses and
other species, whereas types B and C are primarily found in
man. The envelope surface of the influenza virus has viral
proteins. The hemagglutinin (HA) surface protein is responsible for attachment of the virus to sialic acid-containing receptors and viral entry by membrane fusion. The neuraminidase (NA) surface protein is a receptor-destroying enzyme
which plays important roles in viral release and cell-to-cell
spread [6,7]. Influenza A viruses can be further divided into
different subtypes of HA and NA. There are 17 HA subtypes
of influenza virus whereas 9 subtypes of NA are known to be
present [8].

Licensed Influenza Vaccines
Conventional inactivated influenza vaccines
The first vaccines using whole- inactivated influenza virus
were approved for use in the United States in 1945 [9,10]. Inactivated influenza A and B virus vaccines have been extensively used in humans. The vaccines consist of purified virus
that has been chemically inactivated with formalin or β-pro
piolactone. Influenza B viruses, the H1 and H3 subtypes of
influenza A viruses can cause epidemic infections in the human population. Therefore, current vaccines against influenza epidemics contain two influenza A subtypes (H1N1 and
H3N2) and one or two variants of influenza B virus. The composition of the trivalent vaccine contain two influenza A subtypes (H1N1 and H3N2) and one variant of influenza B virus,
which is based on the strains of virus that are expected to circulate in the human population during the winter flu season.
The influenza A subtypes of vaccine strains are adapted to
grow in embryonated eggs, or may be reassortant viruses containing HA and NA of strains needed for vaccination and other remaining genes (polymerase basic protein [PB] 1, PB2,
polymerase acidic protein [PA], nucleoprotein [NP], M1-M2,

NS) which encode the internal proteins from A/Puerto Rico/8/34 (PR8) (H1N1) virus which confer high growth capacity in eggs [11].
Since the dissolution of the lipid envelope still retain the
major antigen HA protein and its immunogenicity with reduction in reactogenicity, detergent mediated disrupting
(splitting) influenza viruses to produce subvirion preparations has been most commonly used in recent vaccines. Although whole-virus vaccines are still in use in some countries
and are highly effective, most vaccines manufactured since
the 1970s have been ‘split’ preparations [12-15].
Live attenuated influenza virus (LAIV) vaccines
Another platform of influenza vaccines was developed to overcome the variable efficacy of the inactivated vaccine, its short
duration of protective immunity, and low capacity to induce
local or cellular immunity. LAIV vaccines administered via
nasal spray (FluMist) have been successfully developed. These
LAIV strains have the properties with cold-adapted (ca) (i.e.,
they replicate efficiently at 25°C, a temperature that is restrictive for replication of most wild-type viruses); temperaturesensitive (ts) (i.e., they are restricted in replication at 37°C or
39°C); and are attenuated (att) to prevent illness. LAIV is a reassortant of internal proteins of a master donor virus and surface proteins (HA, NA) of a wild-type influenza virus. The
strains of A/Ann Arbor/6/60 and B/Ann Arbor/1/66 were developed as master donor viruses which acquired the ca, ts,
and att phenotypes as a result of multiple mutations in the
gene segments that encode internal viral proteins [16].
The efficacy of LAIV is relatively high in children compared
to the inactivated vaccines [17,18]. Intranasal delivery of LAIV
is likely to induce both serum IgG and mucosal IgA antibodies [19]. Unlike inactivated vaccines, LAIV evokes mucosal
and systemic humoral and cellular immunity against native
HA and NA glycoproteins similar to those by natural influenza infection. LAIV is considered to be safe and well tolerated
in children aged over 2 year and adults, but some concerns
have been raised regarding its safety in younger children and
subjects with previous asthma or recurrent wheezing [20,21].
However, LAIV is less effective in adults, and thus it is not approved for use in persons over the age of 50, and inactivated
split vaccines are recommended for adult populations [18,22].
Currently, five seasonal LAIV backbone strains reached re
gulatory approval status: A/Len/134/17/57, A/Len/134/47/57,
B/USSR/60/69, A/Ann Arbor/6/60, and B/Ann Arbor/1/66.
With the exception of the A/Len/134/47/57 strain, all are pres-
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ently used as master donor strains in the production of seasonal LAIV vaccines. LAIV is licensed under the trade name
FluMist in the United States and Canada, and Fluenz in Europe. Early animal experimental data suggest that a new class
of ‘replication-deficient vaccine’ could be developed in the
more distant future, with the plausibility of combining the
contrasting theoretical advantages of both LAIV and the inactivated vaccines [23].
Quadrivalent influenza vaccines
Circulating influenza viruses are either Yamagata-like or Victoria-like strain. Unfortunately, approximately 2% of the type
B influenza viruses matched the vaccine strain (called the
“Victoria” strain) during the 2007-2008 influenza season in
the United States. The following season, 2008-2009, only 17%
of type B influenza detected by surveillance matched the vaccine strain which was the “Yamagata” strain. Type B viruses
of a strain different than the vaccine can circulate, causing
disease due to a mismatch on the type B strain. Vaccine manufacturers have been working on a “quadrivalent” vaccine
that contains four strains of influenza to address this type B
mismatching, which contains two subtype A strains (H1N1,
H3N2) and two type B strains (Victoria, Yamagata). The first
quadrivalent LAIV vaccine was MedImmune’s nasal spray
vaccine, FluMist quadrivalent and licensed by Food and Drug
Administration (FDA). Sanofi Pasteur also announced the results of its Phase II and Phase III clinical trials of their injectable quadrivalent influenza vaccine. New quadrivalent vaccines in addition to the trivalent influenza vaccines are on the
market.

Experimental Universal Vaccines
Influenza viruses are continuously evolving, introducing various mutations in particular to the surface major glycoprotein
HA. Most commonly, these changes result from point mutations in the viral genome RNA encoding HA, and are responsible for emergence of new strains responsible for seasonal
epidemics. Influenza A viruses sometimes emerge with novel
surface proteins that are completely unrelated to pre-existing
human strains, as a result of introduction of new HA and/or
NA genes from other species. These “major antigenic shifts”
result in novel antigenic subtypes of the HA and/or NA glycoproteins that had not previously infected most of the human
population, and therefore can spread rapidly causing global
disease pandemics. Three global pandemics of influenza oc14
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curred during the 20th century, which were caused by H1N1
subtype viruses in 1918, H2N2 viruses in 1957, and H3N2 viruses in 1968. In addition to the human influenza subtypes,
avian origin influenza viruses including H5N1, H7N2, H7N3,
H7N7 and H9N2 subtypes were reported to overcome the
species barrier and to infect humans [24-29]. There was a recent outbreak and report on significant mortality as a result
of H7N9 avian influenza virus transmission to humans [30].
The continuous emergence of highly pathogenic avian influenza H5N1 viruses in domestic poultry and the repeated cases of direct transmission of avian viruses to humans underscore a persistent threat to public health [31-35]. The 2009
outbreak of a new swine-origin H1N1 pandemic virus represents a good example of how fast a new pandemic virus can
spread in the human population once it acquires the ability
to transmit among humans [36,37]. The presently used vaccination programs showed a significant delay in controlling the
spread of new pandemics. Indeed, the recent experience with
the 2009 H1N1 virus demonstrates the high priority to develop novel vaccines to overcome the limited efficacy of current
strain-specific vaccines based on HA as well as improved me
thods of immunization.
A truly universal vaccine should be able to protect against
all subtypes of influenza A viruses and both lineages of influenza B viruses. However, it would be extremely difficult to develop such a universal vaccine that protects against both types
of influenza A and B viruses. Due to more variants of influenza A types in both humans and animals, developing universal
vaccines have been focused on influenza A viruses. It would
be highly promising to develop a vaccine that is broadly crossprotective compared to currently licensed influenza vaccines.
The concept behind developing universal vaccines is to utilize the highly conserved antigenic target and to make it immunogenic sufficient enough for inducing protective immunity (Table 1). The M2 ion channel protein and the stalk domain (HA2) of HA of influenza A virus have been extensively
investigated as a promising antigenic target for developing a
universal vaccine.
Universal vaccines based on influenza virus M2
Influenza virus M2
M2 is a pH-dependent proton-selective ion channel protein
and plays a role during virus entry [38-40]. M2 is a specific
target of anti-influenza drugs such as amantadine and rimantadine [41,42]. The amino acid sequence in the extracellular
domain of M2 (M2e) is highly conserved among human in-
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Table 1. Viral antigenic targets of influenza vaccines
Viral protein

Targeted site

Hemagglutinin (HA1) Receptor binding globular head
domain
Hemagglutinin (HA2) Stalk domain with fusion
activity
Matrix 2 ion channel Ectodomain of M2 (M2e)
(M2)
Nucleoprotein (NP) T-cell epitopes
Neuraminidase (NA) Conserved sialidase active site
Matrix (M1)
T-cell epitopes

Proposed mechanism(s) of protection
Strain specific neutralizing antibodies block the virus entry; weak cellular immunity
(Non-neutralizing) antibodies, inhibition of fusion, maturation of the HA, and antibody dependent
cell-mediated cytotoxicity
Non-neutralizing antibodies, alveolar macrophages, Fc receptor, antibody dependent natural killer cell activity,
complement mediated lysis, antibody dependent cell-mediated cytotoxicity, CD4 and CD8 T cell mediated protection
Cell lysis by CD8+ cytotoxic T-lymphocytes (CTL), CD4+ T lymphocyte mediated cytolysis
Non-neutralizing antibodies, Inhibition of virus release, virus spread
Cell lysis by CD8+ CTL, CD4+ T lymphocyte mediated cytolysis

fluenza A viruses. For example, the N (amino)-terminal epitope SLLTEVET (residues 2-9) in M2e was found to be conserved at a rate of 100% among human influenza A virus isolates and approximately over 99% among all influenza A subtypes [43,44].
M2e conjugate vaccines
The extracellular 23-amino acid residue of the M2 protein
(M2e) is a poor immunogen in its own. Even mice infected
with influenza virus do not induce high levels of antibodies
recognizing M2 (data not shown). Nonetheless, M2e specific
monoclonal antibodies were shown to reduce the plaque size
or the growth of some influenza A virus strains in vitro [4547]. Passive transfer of M2 monoclonal antibodies was shown
to protect mice by lowering lung virus titers upon subsequent
infection with influenza A virus [48,49]. Therefore, induction
of adaptive anti-M2 immunity would be a cost effective and
practical strategy for controlling influenza epidemics or pandemics.
Because of low immunogenic property of M2, different approaches to link M2e peptide to carriers and/or use of potent
adjuvants were explored. The first study on protection was
reported with a full-length M2 vaccine expressed in insect
cells after immunization of mice in the presence of incomplete Freund’s adjuvant [50]. This recombinant M2 vaccine
providedsurvival protection [50]. Since then, many studies
have reported recombinant M2e fusion constructs using a
variety of carrier molecules or systems: hepatitis B virus core
(HBVc) particles [51-53], human papillomavirus L protein virus-like particles (VLPs)[54], phage Qβ-derived VLPs [55],
keyhole limpet hemocyanin [56], bacterial outer membrane
complex [52,57], liposomes [58], and flagellin [59]. Using various adjuvants inappropriate for human use, recombinant
M2e-carrier vaccines were demonstrated to provide protec-

tion against lethal challenge with H1N1, H3N2, and H5N1 influenza A viruses. In particular, different forms of M2e vaccines fused to the HBVc VLPs were shown to induce high levels of anit-M2e antibody responses [43,51,60-62]. However,
M2e-mediated protection by conjugate vaccines was relatively much weaker than HA-mediated protection [63]. Also,
M2e antibodies induced by conjugate vaccines were not effective in binding to the virus [63]. Probably, chemical or genetic fusion of M2e would not be effective in inducing antibodies recognizing M2 in a native conformation on virus [63].
A novel approach was pursued in an attempt to facilitate the
formation of tetrameric structure of M2e. Genetically linking
M2e to the tetramer-forming leucine zipper domain of the
yeast transcription factor general control nondepressible-4
(GCN4) was demonstrated to form recombinant tetrameric
M2e vaccines [64]. The recombinant M2e-GCN4 conjugate
vaccine induced M2e-specific antibody responses conferring
100% survival protection to vaccinated mice [64].
M2e VLP vaccines
Enveloped VLPs expressing HA and/or NA were demonstrated to be immunogenic and induce protective immunity [6568]. Therefore, we explored an alternative approach to express M2 proteins in a membrane-anchored form mimicking
the native conformation of M2. A full-length M2 was presented on influenza M1-derived VLPs containing M2 alone (M2
VLPs) without HA and NA to avoid the shielding effect by
large size glycoproteins [69]. Mice vaccinated with M2 VLP
vaccines induced higher levels of M2e specific antibodies
than those by whole inactivated influenza virus vaccination
[70]. In addition, M2e specific antibodies induced by M2 VLP
vaccination via the intranasal route were cross reactive to and
protective against diverse subtypes H1N1, H3N2, and H5N1
influenza viruses [69,70]. However, the wild type M2 protein
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was incorporated into VLPs at low levels similar to those in
influenza viruses [69]. The levels of M2 specific antibodies
were relatively very low and substantial weight loss was observed in M2 VLP alone immunized mice after lethal challenge [69].
There is another caveat in developing truly universal vaccines based on M2e. There are few amino acid variations depending on the host species (human, avian, swine, equine,
and other hosts) where influenza viruses were isolated [43,44].
The five amino acids within the residues 10-20 of M2e (underlined residues) were observed to be host restricted: PIRNEWGCRCN (aa 10-20, human isolates), PTRNGWECKCS (aa 1020, avian isolates), LTRNGWGCRCS (aa 10-20, avian origin
human isolates), and PIRNGWECRCN (aa 10-20, swine isolates) [44,71]. Therefore, to improve the protective efficacy of
M2e vaccines, we genetically engineered a tandem repeat of
M2e epitope sequences (M2e5x) of human, swine, and avian
origin influenza A viruses, which was expressed in a membrane-anchored form and incorporated in VLPs [71]. In addition, the chimeric M2e5x construct with the transmembrane
domain being replaced by that of HA was found to incorporate heterologous M2e epitopes into VLPs at a several hundred-fold higher level than that on influenza virions or the
wild type M2 VLPs [71,72]. Intramuscular immunization with
M2e5x VLP vaccines was highly effective in inducing M2e
specific antibodies reactive to different influenza viruses, mucosal and systemic immune responses, and cross-protection
regardless of influenza virus subtypes in the absence of adjuvant. Importantly, immune sera were found to be sufficient
for conferring protection in naïve mice, which was long-lived
and cross protective. Anti-M2e antibodies induced by heterologous M2e5x VLP immunization conferred a wider range
of cross reactivity to influenza virus at higher levels than those
by live virus infection, homologous M2e VLPs, or M2e monoclonal antibody 14C2 [72]. As a protective mechanism via M2emediated immunity, Fc receptors were found to be important
for mediating protection by immune sera from M2e5x VLP
vaccination [72]. Thus, molecular designing and presenting
M2e immunogens on the surfaces of VLPs provide a promising platform for developing universal influenza vaccines without using adjuvants, which can be more effective in inducing
protective M2e immunity than natural virus infection and
further supports an approach for developing an effective universal influenza vaccine.
M2e antibodies have virus non-neutralizing property. M2e
based immunity alone is infection-permissive and is difficult
16
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to eliminate disease symptoms so far even in animal models.
A desirable universal influenza vaccine should be able to diminish both morbidity and mortality. A novel approach is to
use such vaccines of conserved antigenic targets as adjunct
to current vaccine formulations with a variable antigenic target HA. In this regard, use of M2e-based VLP vaccines as a
supplement could significantly improve the efficacy of cross
protection by HA-based current vaccines. Wild type M2 presented on VLPs in a membrane-anchored form was found to
significantly improve cross protection when used in combination with inactivated whole viral vaccine in mice [70]. Mice
that were intranasally immunized with a mixture of an inactivated virus and wild type M2 VLP were protected against a
low dose of challenge virus from both mortality and morbidity. In addition, M2 VLP-supplemented inactivated influenza
virus vaccine (A/PR/8/34, H1N1) conferred broad cross protection to the immunized mice against lethal challenge with
2009 H1N1 pandemic virus, heterosubtypic H3N2, or H5N1
influenza viruses [70]. The concept of M2 VLP supplementation to improve cross protection was extended to the seasonal
influenza split vaccines as well as to the more commonly used
route of intramuscular immunization (unpublished data).
Intramuscular immunization with H1N1 split vaccine (A/
California/07/2009) supplemented with heterologous tandem repeat M2e5x VLPs induced M2e specific humoral and
cellular immune responses contributing to improved cross
protection of licensed split vaccines. More importantly, supplementation of M2e5x VLPs was able to shape the host responses to the split vaccine in the direction of T helper type 1
responses inducing dominant IgG2a isotype antibodies as
well as interferon gamma (IFN-γ) producing cells in systemic
and mucosal sites (unpublished data). These recent new approaches support evidence that supplementation of split vaccines with M2e5x VLPs is a promising new vaccination for
overcoming the limitation of strain-specific protection by currently marketed influenza split vaccines.Ultimately, clinical
trials should be carried out to validate this supplementation
method as a potential universal vaccine for human use.
Influenza M2-mediated immunity
The protective immune mechanisms of the immune responses induced by M2 vaccination remain to be fully elucidated
and further studies are needed for a better understanding
(Table 1). Antibody-dependent, natural killer cell mediated
cytotoxicity was found to be important for conferring protection by vaccination with M2e-hepatitis B core vaccine [63].
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Another M2e-carrier vaccine using Mycobacterium tuberculosis heat shock protein 70 (M2e-HSP70359-610) was shown to
provide protection via alveolar macrophages and Fc receptordependent elimination of influenza A virus-infected cells [73].
We demonstrated that dendritic and macrophage cells were
needed for protection by immune sera of M2 VLP vaccination in a mouse model since depletion of these cells using
clodronate-liposomes abrogated the protection [69,70]. Other studies suggest that M2 antibodies can restrict the growth
of influenza viruses as shown by inhibiting the plaque size or
replication of in vitro cultured viruses [45,74,75]. Our recent
studies also found that Fc receptors played an important role
in conferring protection by M2e immunity of M2e5x VLP immunization [72]. Multiple mechanisms are likely to be involv
ed in conferring protection against influenza after immunization with M2 based vaccines.
Clinical trials of influenza M2 vaccines
The efficacy of some early recombinant M2e vaccines has
been tested in human clinical trials. Sanofi Pasteur Biologics
Co., formerly Acambis (Cambridge, MA, USA) reported the
safety and immunogenicity of a recombinant vaccine candidate, M2e-HBc fusion protein (ACAM-FLU-A) in its Phase I
trial study [76]. The ACAM-FLU-A vaccine was demonstrated
to be immunogenic and well-tolerated with no significant
side-effects. M2e-HBc carrier protein vaccine also conferred
partial protection of 70% survival from infection by the highly
lethal avian H5N1 influenza strain in ferrets a more relevant
animal model. The flagellin-adjuvanted HA fusion protein
vaccine was tested in a clinical trial and shown to be immunogenic in elderly vaccinees [77]. An M2e-flagellin fusion vaccine (STF2.4xM2e) was also tested in healthy young volunteers, aged 18-49 as reported in the first Phase I clinical trial
study by VaxInnate Corp. (Cranbury, NJ, USA) [76,78]. Low
doses of flagellin-M2 vaccines (0.3 and 1.0 µg doses) were
found to be safe and tolerated in subjects tested. Also, these
M2e-flagellin conjugate vaccines were immunogenic in 75%
vaccinees after the first dose and 96% after the second dose
[76,78]. However, two high doses (3 and 10 µg doses) of flagellin-M2 vaccines were associated with the appearance of
adverse effects of illness symptoms in some of the subjects.
Therefore, toxicity of flagellin adjuvant might be an issue at
higher doses of vaccines. Development of a safer vaccine
based on M2 will be needed and VLP-based vaccines can be
an attractive candidate without using additional adjuvants.
These clinical trials merit further studies for developing safe

and effective universal influenza vaccines.
Cross protective immunity by hemagglutinin stalk domain
(HA2) vaccines
Functionally, influenza virus HA is composed of a receptor
binding globular head domain of HA1 and a membrane-fusion inducing stalk domain of HA2 for virus entry [79]. Current influenza vaccination is based on immunity to the globular head domain of HA1 surrounded by variable antigenic
sites contributing to the generation of numerous escape mutants [80,81]. The failure or low efficacy of influenza vaccination is primarily due to mutations occurring in the HA1 globular head domains of predicted influenza virus pathogens
[82,83].
In an effort to identify conserved epitopes, recent studies
have provided evidence that the HA stalk domain can be a
potential target for developing universal vaccines. The sequence homology of the HA2 subunit among different subtypes is in a range of 51-80%, and the sequence conservation
of HA2 is relatively higher than that of the HA1 subunit domain which is in a wider range between 34% and 59% [84].
The sequence conservation of the HA2 subunit among influenza virus strains within the same subtype is even higher [84].
In particular, specific regions in the HA stalk domains were
identified to be highly conserved among different subtypes of
influenza viruses, which can be divided into two main phylogenetic groups [8]. The group 1 includes the subtypes of H1,
H2, H5, H6, H8, H9, H11, H12, H13, H16, and H17. The group
2 contains the subtypes of H3, H4, H7, H10, H14, and H15. A
long α-helix domain in the HA2 subunit (the 76-130 amino
acid region) was shown to have this conservation among different HA subtypes [85,86].
Recent studies demonstrate the feasibility of stalk domainbased vaccines. The chemically synthesized fusion peptide
(amino acids 1-38 of HA2) was conjugated to the keyhole limpet hemocyanin and tested in mice as a vaccine [87,88]. Similarly, this vaccine provided survival protection against a low
dose challenge with homologous and heterologous virus in
immunized mice but showed severe weight loss, indicating
its incapability of preventing illness [87,88]. A long α-helix
HA2 vaccine consisting of the amino acid 76-130 polypeptide
was coupled to the carrier protein keyhole limpet hemocyanin and its vaccine efficacy was tested I a mouse model [85,86].
Sera from immunized mice with an α-helix HA2 conjugate
vaccine showed substantial binding antibodies reactive to
heterosubtypic viruses [86]. This α-helix HA2 vaccine could
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confer partial survival protection against heterosubtypic challenge viruses (A/PR8 H1N1, A/Vietnam/04 H5N1 virus) and
the homologous virus H3 subtype. Although the HA2 vaccine
immune sera showed broader cross-reactivity with different
HA molecules, the breadth was limited to the group 2 HAs
(subtypes H3, H4, H7, H10, H14, and H15).
Using recombinant genetic engineering techniques, headless HA constructs that were composed of membrane-proximal portions of both the HA1 signal peptide region and HA2
subunits were stably expressed on the cell surfaces [89]. As
well, these headless HA constructs were intended to avoid
the highly immunogenic head domain. Co-expression of the
human immunodeficiency virus (HIV) Gag core protein and
headless HA protein by transient DNA co-transfections produced chimeric Gag VLPs containing headless HA molecules
[89]. Two times vaccinations with DNA constructs (Gag+HA)
were followed by boost immunization with chimeric headless HA VLP vaccines in the presence of Freund’s complete
adjuvant [89]. Immunization of mice with Headless HA VLP
vaccines provided protection against homologous challenge
with moderate body weight loss. The neutralizing activity in
immune sera of mice with headless HA VLP vaccines was not
conclusively confirmed [89]. Nonetheless, headless HA (A/
PR8) VLP immune sera were likely to show greater reactivity
to heterologous strains than the full-length HA vaccine [89].
A/Hong Kong/68 headless HA VLP vaccines did not induce
antibodies cross reactive to different group 1 HAs (subtypes
H1, H2, H5, H6, H8, H9, H11, H12, H13, and H16). Vaccines
of influenza virions stripped of HA1 by treatment with acid or
dithiothreitol were found not to be effective in inducing cross
reactive antibodies and cross protection compared to the untreated control vaccines [90,91]. Possible limitations of these
approaches include a low yield of headless HA VLPs produced
by transient DNA transfection, use of Freund’s adjuvant, and
limited breadth due to the specificity of reactivity to certain
HA subtypes.
Heterologous prime-boost immunization strategies may
elicit cross-reactive anti-HA antibodies. A recent study from
the Palese group demonstrated that prime-boost immunizations with chimeric HA influenza vaccine constructs could
elicit broadly cross reactive stalk-specific antibodies [92]. Mice
were repeatedly immunized with serial chimeric HA protein
constructs of H7 HA head domain plus the H3 stalk domain,
H5 HA head domain plus the H3 stalk domain, and H4 HA
head domain plus the H3 stalk domain. After challenge of
mice that were multiple times immunized with chimeric HA
18
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proteins, the immune sera were found to contain cross protective antibodies likely targeted to the stalk domain [92]. Interestingly, the stalk domain responsive antibodies were induced by H3N2 influenza virus infection but not by immunization with inactivated influenza virus vaccines [93]. Interestingly, when human subjects who were first primed with an
H5 HA DNA vaccine were then boosted with an inactivated
H5 vaccine, substantial levels of anti-HA stalk domain antibodies were elicited, which showed cross neutralizing activity
against the group 1 viruses [94]. However, no promising and
effective vaccines capable of inducing antibodies targeted to
the stalk domain, which are protective regardless of HA subtypes, have been developed yet. Further development of these
vaccines based on the stalk domain of HA would likely contribute toward universal influenza vaccines.

T Cell-Based Vaccines for Heterosubtypic
Protection
Seasonal influenza viruses undergo continuous mutation in
the antigenic sites of HA and NA molecules, which allow variants to escape from the neutralizing antibody responses. Since
the majority of cytotoxic T lymphocytes (CTLs) can recognize
relatively conserved viral proteins such as the NP, the PA and
the matrix 1 protein (M1), they are able to contribute to heterosubtypic immunity between different subtypes [95,96].
It has been recognized that CTLs play a key role in eliminating influenza virus infected cells by inducing apoptosis
through contact-dependent interactions [97]. There is evidence for the role of influenza virus-specific CTLs, which are
elicited by vaccination or virus infection, in protection against
infection with influenza A virus of different subtypes (Table
2). Previous studies have demonstrated that influenza virusspecific CTLs provide protective heterosubtypic immunity,
which are confirmed by depletion in influenza virus-infected
mice or adoptive transfer of influenza virus-specific CTLs into
naïve mice [95,98,99].
The majority of T cell-mediated vaccines target highly conserved internal proteins such as NP, PA and M1 proteins. The
different approaches for T cell-based vaccine development
have been used, which include the LAIVs, plasmid DNAs, viral vectors (modified vaccinia Ankara strain), and VLPs (Table
2). These T cell-based vaccines can also induce humoral antibody responses. One of popular trial is the use of LAIV which
can be generated by adaptation at low temperatures. In humans, LAIV vaccination induced strong IFN-γ-producing
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Table 2. The evidence of the role of T cells in heterosubtypic immunity
Infection or vaccination
H1N1 [95]

Challenge
H3N2

Approach

Comments

Depletion of T cells

CTLs reduced viral infection and conferred protective heterosubtypic
immunity in mice
NP Vaccina virus [98]
H3N2, H1N1
Adoptive transfer of T cells
NP specific-CD8 T cells reduced virus replication and protected mice
against a lethal influenza virus infection in mice
H3N2 [99]
2009 H1N1
Depletion of CD8 T cells
CTLs conferred protection against 2009 H1N1
LAIV H1N1 [100]
Intracellular cytokine staining of CD4 IFN-γ-producing T cells in blood were increased 10 days post vaccination
and CD8 T cells
in humans
LAIV H3N2 [102]
H1N1
Tetramer staining and depletion of CD4 Depletion of CD8 T cells abrogated protection against a lethal
or CD8 T cells
heterosubtypic influenza infection in mice
NP DNA (H1N1) [103]
H3N2
Adoptive transfer of NP specific T cells NP-specific CTLs conferred protection in naïve mice
NP DNA plasmid [104]
H1N1, H5N1
Depletion of CD4 or CD8 T cells
Depletion of both CD4 and CD8 T cells reduced survival rate after mice
challenged with influenza viruses in mice
HA-VLPs [106]
H1N1, H2N2
Depletion of CD8 T cells
Survival rate was diminished after administration of anti-CD8 depletion
antibody in mice
MVA-NP+M1 (H3N2, A/ H3N2 (A/Wisconsin/ CTLs
Influenza virus specific CTL and virus shedding were determined in humans
Panama/2007/1999) [109] 67/2005)
CTL, cytotoxic T-lymphocyte; NP, nucleoprotein; LAIV, live attenuated influenza virus; IFN-γ, interferon gamma; VLP, virus-like particle.

CTLs than inactivated influenza vaccine [100]. Of interest,
conserved NP-, PA-, and PB1-specific CD4 and CD8 T cells
generated after attenuated cold-adapted H3N2 or a 2009
pandemic H1N1 vaccine conferred protection against heterosubtypic lethal challenges in mice [101,102].
In addition to LAIV, DNA vaccination can be another candidate. A previous study has shown that NP DNA vaccination
increased CTL precursor frequency and provided better protection in NP DNA-immunized mice compared to mice vaccinated with HA DNA in response to challenges with heterologous influenza viruses [103,104]. Furthermore, other vaccine
types have been described to induce influenza virus specificCTL responses. Vaccination with complex adenovirus vector
encoding H5, N1 and M1 genes induced antigen specific CTLs
that were able to producing IFN-γ [105]. Recently, mice that
were immunized with VLPs containing HA protein derived
from PR8 were protected against homologous and heterosubtypic influenza virus infections and this protection was
dependent on HA-specific CTL responses [106].
There is evidence that virus-specific CTLs can afford protection against a variety of influenza virus subtypes, but it is
also important to consider generating antigen-specific antibody responses directed to external proteins HA and NA as
well as internal proteins. Interestingly, CTLs specific for NP
protein cooperatively synergize protective immunity with
non-neutralizing antibodies [107,108]. Thus, it suggests that
generation of both antigen-specific CTLs and antibodies is
prerequisite for robust protective immunity against hetero-

subtypic influenza virus infections in human.
The replication defective vaccinia Ankara strain (MVA) expressing M1 and NP from A/Panama/2007/1999 virus (H3N2)
(MVA-NP+M1) was tested in recent clinical trials [109]. Individuals were immunized with MVA-NA+M1 or unimmunized
prior to challenge with A/Wisconsin/67/2005 H3N2 virus.
Higher levels of influenza-specific CTL responses were observed compared to unvaccinated controls. Also, those who
were vaccinated showed fewer days of virus shedding than
unvaccinated control subjects. However, fewer numbers of
subjects were enrolled and further validation with a larger
number of subjects is warranted.

Roles of Innate Immunity in Vaccination
Recognition of microbial pathogens and vaccine antigens is
an essential element for initiating adaptive immune responses as well as determining the quality of resulting host immune
responses. Dendritic cells (DCs) and macrophages play a critical role in inducing protective adaptive immune responses
of both T and B cells. We found that presenting HA antigen
on VLPs was significantly much more effective in inducing
protective T cell and B cell responses than the soluble HA protein antigen [110]. Effective induction of protective immunity
by antigens in a VLP form is probably because particulate antigens are more likely to activate innate immune cells such as
DCs.
Antigen-presenting cells (APCs) such as DCs and macro-
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phages prominently express toll-like receptors (TLRs) which
recognize pathogen, vaccine antigen, or adjuvant components.
APCs play critical roles in activating innate immunity by recognizing and capturing pathogens or vaccine antigens at the
site of infection or vaccination via receptors such as TLRs.
Antigen-loaded APCs initiate the events of inducing the activation of adaptive T and B cells [111]. In cases where vaccine
antigens (such as subunit vaccines) are not effective in stimulating APCs, adjuvants should be included in the vaccine formulation to activate APCs. Some compounds enhancing antigen depot or activating innate immunity by interacting with
pathogen recognizing receptors (PRRs) such as TLRs have
shown some promise. For example, alum, MF59, or AS04 (TLR
agonist) adjuvants are often added to the subunit vaccine formulations. But live attenuated (cold-adapted) influenza vaccines are likely to activate TLR3 and 7 during viral replication
intra-cellularly leading to the up-regulation of inflammatory
cytokines [112], and thus adjuvants are not needed. Also, the
live attenuated yellow fever vaccine, one of the most effective
vaccines, was demonstrated to activate multiple DC subsets
via TLRs 2, 7, 8, and 9 [113]. Activated DCs up-regulate costimulatory molecules through receptor-mediated recognition of a pathogen or vaccine antigen and can elicit the differentiation of naïve T cells into different effector T cells leading
to the generation of cytotoxic CD8 T cells and activated B cells
[111].
B cells are one of the important adaptive immune cells.
Previous studies suggest that follicular B cells express TLR 1,
2, 4, 7, and 9. These B cells also showed proliferative responses and isotype switching upon the in vitro stimulation with
TLR2 (Pam3Cys), TLR3 [poly(I:C)], TLR4 (lipopolysaccharide
[LPS]), TLR7, and TLR9 agonists [114]. There have been controversies concerning whether TLR signaling is essential for B
cell responses after vaccination. The addition of TLR9 ligand
CpGs to B cells in vitro cultures induced the production of IgG2a, IgG2b and IgG3 antibodies [115]. An innate adaptor signaling molecule, myeloid differentiation factor-88 (MyD88),
is known to be a key adaptor componentfor activation from
the most TLRs except the TLR3 [116]. MyD88-deficient mice
have been shown to have a defect in inducing T helper type 1
immune responses to ovalbumin plus complete Freund adjuvant [117]. Importantly, we found that MyD88-deficient
mice showed a significant defect in generating T helper type
1 isotype switched antibodies, and interferon (IFN-γ) secreting T cell responses as well as for eliciting long-lived antibody
secreting plasma cells and protective immunity after vaccina20

http://www.ecevr.org/

tion with influenza VLP vaccines [118]. Better understanding
of stimulating innate immune components by vaccine antigens will provide informative insight into developing effective
and safe vaccines.
Initially, TLRs were recognized as a family of PRR host cell
proteins that recognize a wide range of pathogen-associated
molecular patterns (PAMPs) in the microbial pathogens or
vaccine antigens [116,119]. To date, 10 and 13 functional TLRs
have been identified in humans and mice, respectively. TLR1,
TLR2, TLR4, TLR5, TLR6, and TLR11 are expressed on the
host cell surface. TLR3, TLR7, TLR8, TLR9, and orphan receptor TLR13 are expressed within intracellular compartments
such as endosome and recognize nucleic acids [116,120]. TLR1,
TLR2, and TLR6 recognize pathogen-derived molecules such
as lipoproteins. TLR3 binds to double-stranded (ds) RNAs
that are present in many RNA viruses including influenza virus. TLR4 recognizes bacterial LPS, fusion protein of respiratory syncytial virus, fibronectin, and heat-shock proteins.
TLR5 is known to recognize bacterial flagellin molecules.
TLR7 and TLR8 are activated by single-stranded (ss) RNA
molecules that are present in RNA viruses such as influenza
virus whereas TLR9 recognizes bacterial unmethylated DNA
molecules. Once TLRs recognize various components of vaccine antigens or microorganisms including viruses, inflammatory cytokines are produced, which initiate the activation
of signaling cascade leading to the induction of adaptive immune responses to pathogens or vaccine antigens.
Another important family of PRRs includes the C-type lectin receptors (CLRs), cytosolic proteins such as NOD-like receptors (NLRs) and cytoplasmic RNA helicase retinoic acid
inducible gene I (RIG-I) or melanoma differentiation associated gene 5 (named RIG-I like receptors, RLRs) [121]. The
representative CLRs are DC-specific ICAM-3 grabbing nonintegrin and DC-associated C-type lectin-1 (dectin-1), both
of which play key roles in inducing immune responses in response to fungal, bacterial or virus pathogen molecules. NLRs
are expressed intracellulary and respond to various PAMPs to
trigger inflammatory responses [121].
TLRs are expressed on various immune cells including ma
crophages, DCs, B cells, specific T cells and even expressed on
non-immune cells such as fibroblasts and epithelial cells [114,
122,123]. All TLRs except TLR3 use the downstream adaptor
molecule MyD88, whereas TLR3 and TLR4 in part use Toll
receptor-associated activator of interferon (TRIF). After TLRsligand interaction, TLR activation results in triggering of downstream signaling cascades through the engagement of signal-
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ing intermediates, MyD88, Toll-interleukin (IL)-1 receptorassociated-protein (also known as MAL), TRIF, Toll receptorassociated molecule, IL-1 receptor associated kinase, and tumor necrosis factor receptor-associated factor 6. TLR ligation
can result in activation of transcription factors (IRF3, IRF7,
activator protein-1, nuclear factor-κB) and consequently produce the proinflammatory cytokines and chemokines. Furthermore some TLRs (TLR3, 4, 7, 8, 9) are capable of inducing
type 1 interferons (IFN-α/β) to elicit antiviral responses [116].

Vaccine Adjuvants
Adjuvants are used as vaccine additives to lower antigen loads
in a vaccine or to increase vaccine efficacy [124]. Adjuvants
modulate host immune responses and magnify immunogenicity of the vaccine. In general, influenza vaccine such as split
vaccine or live attenuated vaccine can elicit host immune responses in primed healthy individuals without adjuvants.
However, in the elderly or immune-compromised populations, adjuvants are needed to increase responsiveness to the
vaccine [125]. Adjuvants have a critical role in inducing innate, adaptive and memory immune responses to some vaccine antigens.
Representative adjuvants and their possible action mechanisms are listed in the Table 3. Aluminium adjuvant (Alum) is
the most commonly used vaccine adjuvants. It has been used
for more than 70 years because of its safety and capacity of
making antigen depot [126]. Alum adsorbs the vaccine antigen and makes the antigen stay longer in the injection site, so
that immunogenicity of the antigen is increased. In an immunological mechanism study, alum was shown to activate

NALP3 inflammasome and induce IL-1β production to stimulate the innate immune system. Alum is likely to induce T
helper type 2 immune responses to co-administered antigens
in humans [127].
MF59 is an oil-in-water emulsion type of adjuvants, and
composed of squalene, polysorbate 80, sorbitan trioleate, trisodium citrate dehydrate, citric acid monohydrate and water
for injection [128]. MF59 adjvuant is used in influenza vaccine (Fluad) and pandemic flu vaccine. Use of MF59 adjvuant
resulted in stronger antibody responses and vaccine antigen
dose sparing effects [129]. MF59 stimulates cells in the sites of
injection to express chemokines and cytokines. These chemokines and cytokines recruit innate immune cells and APCs.
Some antigen presenting cells subsequently uptake antigenMF59 complex and migrate to draining lymph nodes for the
induction of adaptive immune responses [130,131]. AS03 is a
modified form of MF59 and is an oil-in-water emulsion with
a tocopherol. This form of adjuvant was used in pandemic
influenza vaccine (Pandemrix) [132]. TLR agonists are considered as potential adjuvants, so many different kinds of TLR
agonists have been tried in experimental animal models and
clinical trials. AS04, which contains Alum and monophosphoryl lipid A (MPL), is a licensed adjuvant in hepatitis B virus (HBV) vaccine (Fendrix) [133] and human papillomavirus vaccine (Cervarix) [134]. MPL is a detoxified form of LPS,
which is a TLR4 agonist. It can activate immune cells such as
monocytes and myeloid dendritic cells directly to induce immune responses to the vaccine antigen [124]. Flagellin, a TLR5
agonist and a motor apparatus of bacteria, can induce mixed
T helper types 1 and 2 immune responses. Flagellin-antigen
fusion proteins were developed to magnify the vaccine and

Table 3. Various adjuvants used in vaccines
Adjuvants
Alum
MF59
AS03
AS04
Flagellin
Imiquimod
CpG DNA
QS21

Major components

Mechanism of action

Used vaccines

Aluminium hydroxide
Oil in water emulsion
Oil in water emulsion with tocopherol
MPL (TLR4 agonist) + Alum
Flagellin (TLR5 agonist) or
Flagellin-antigen fusion protein
TLR7 agonist
TLR9 agonist
Saponin from American barks

Antibodies, T helper type 2, adsorb antigen, NARP3 inflammasome
Antibodies, T helper types 1 and 2, stimulate immune cells
Antibodies, T helper types 1 and 2, stimulate immune cells
Antibodies, T helper type 1, TLR4 signaling stimulation, NLRP3 inflammasome
Antibodies, T helper types 1 and 2, TLR5 signaling stimulation

Various human vaccines
Influenza, pandemic flu
Pandemic flu
HBV, HPV
Clinical trial

Antibodies, T helper type 1, TLR7 signaling stimulation
Antibodies, T helper type 1, TLR9 signaling stimulation
Antibodies, T helper types 1 and 2, stimulate immune cells, deliver antigen to
cytoplasm
Antibodies, T helper types 1 and 2, stimulate immune cells
Antibodies, T helper types 1 and 2, stimulate immune cells

Clinical trial
Clinical trial
Clinical trial

Ginseng extract Extract from Panax ginseng
Alpha-GalCer Extract from marine sponge

Clinical trial
Clinical trial

MPL, monophosphoryl lipid A; TLR, toll-like receptor; HBV, hepatitis B virus; HPV, human papillomavirus.
http://dx.doi.org/10.7774/cevr.2014.3.1.12
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adjuvant effects [135]. Imiquimod, a TLR7 agonist, and CpG
DNA, a TLR9 agonist, stimulate plasmacytoid dendritic cells
which can produce type 1 interferons to induce immune responses to intracellular pathogens such as virus [124].
Recently, natural substances have received attention as a
potential adjuvant compounds. QS21, derived from American bark, is a saponin-based adjuvant. QS21 can stimulate
dendritic cells directly and also destabilize the membrane of
the endosome to deliver antigen to the cytoplasm, so that it
can elicit cellular immune responses [136]. Another example
of the natural adjuvants is an extract from Panax ginseng. It
induced a balanced T helper types 1 and 2 immune response
[137]. Many marine organisms, for example, sponge and algae extracts, are also investigated actively in experimental
and clinical level. Alpha-galactosylceramide (alpha-GalCer),
an extract from marine sponge, is known to stimulate natural
killer T cells and induce antibody production, and balanced
T helper types 1 and 2 immune responses [138].

Conclusion
Until now, most licensed influenza vaccines are manufactured by methods that were established more than 50 years
ago despite recent scientific advances in vaccinology. New
vaccines against influenza viruses to improve the breadth of
protection would be feasible but some technical, regulatory,
and logistical challenges remain to be resolved.
Many studies reporting universal influenza vaccines have
focused on conserved single peptides or proteins as target
antigens (M2e, HA2 stalk domain, NP, M1) in the presence of
adjuvants in animal models. These conserved antigenic targets have relatively weak immunogenicity (Table 1). Experimental vaccines based on the HA2 stalk domain or M2e external domain of ion channel protein are not capable of inducing neutralizing antibodies although some monoclonal
antibodies binding to the HA2 stalk domain are known to
have cross neutralizing activity. Immunization with T-cell
vaccines could provide survival protection but not prevent
infection. Therefore, the protective efficacy of these candidate universal vaccines would be lower than strain-specific
HA based vaccines of inducing neutralizing antibodies.
It is needed to develop new qualitative and quantitative
methods to define the potency of the vaccine as well as to identify immune correlates of cross protection. The path to licensure of novel influenza vaccines will require demonstration
of efficacy in humans. Vaccines that do not prevent infection
22
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but ameliorate disease will need a larger scale of clinical trials. Public health authorities will evaluate how truly universal
novel influenza vaccines are. Challenging decisions include
whom to vaccinate and how often the universal vaccine may
require updating.
As alternative approaches to developing truly universal
vaccines, supplementation concept will be proven to be feasible by complementing and broadening the efficacy of current vaccines based on the strain-specific immunity. We have
shown that supplementing the whole inactivated virus with
the conserved M2 VLP vaccine was found to significantly improve the heterosubtypic cross protection [70]. With the emergence of drafting epidemic strains or an outbreak of pandemic, the supplemented vaccination would significantly prevent
the mortality and ameliorate morbidity.
It will provide highly informative insight into developing
novel new vaccines and adjuvants if we better understand
the immunological mechanisms how cross protective vaccines work and by which certain adjuvants enhance the immunogenicity of vaccines. Also, deciphering the roles of innate immune components in contributing to long term protective immunity will be an important area to be explored for
designing and developing effective vaccines. In addition, current vaccines are mostly given by intramuscular injection using syringe-needles and administered by medical personnel.
It is also an important area in vaccine field to develop new
vaccine technologies and alternative routes of immunization
such as needle-free skin delivery, oral, nasal, and sublingual
immunization.
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